Microarray Ltd

Manchester, United Kingdom

Microarray Ltd

Manchester, United Kingdom
SEARCH FILTERS
Time filter
Source Type

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering. This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogenetics. The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies. FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described. Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects. The report includes summary profiles of 69 companies relevant to cytogenetics along with their 80 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified. The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography. For more information about this report visit http://www.researchandmarkets.com/research/9hr5g9/cytogenetics


Visiongain's new report Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques indicates that the...


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Infectious Disease Molecular Diagnostics Market (Hepatitis, HIV/CT/NG/HPV and Other Tests)" report to their offering. Growth is expected to be higher than the overall molecular testing market for the next five years. This is according to Kalorama Information's latest study on the molecular microbiology/virology markets. This category is projected to account for 60% of the global molecular diagnostics market by 2021. The market segment is defined by test decentralization with the introduction of NAAT platforms able to be operated in hospital labs and near-patient points of care such as physician office labs (POLs) and outpatient clinics. Integrated design from sample preparation to results analysis and user friendly features are just as appealing to larger clinical labs to free up personnel. Menu expansion on integrated analyzers has been the predominant focus of competitors in molecular infectious disease diagnostics. Market share and client retention depend on the ability of one platform to perform all routine infectious disease tests. The Molecular diagnostics market is unrivaled among the IVD markets because of its superior technologies in terms of its performance and applicability. Microarray, next-generation sequencing and development-stage isothermal amplification methods represent promising contributions to the market space. For more information about this report visit http://www.researchandmarkets.com/research/sq7gtr/infectious


JERSEY, Channel Islands, May 22, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported continued progress on the commercial scale-up of MosaiQ and financial results for its fourth quarter and fiscal year ended March 31, 2017. “Tremendous progress continues to be made towards the full commercial launch of MosaiQ in Europe later this year. The initial manufacturing system for MosaiQ Microarrays is now commissioned and validated. Working with our partner STRATEC, we have now taken delivery of the first “commercially ready” MosaiQ Instrument” said Paul Cowan, Chairman and Chief Executive Officer of Quotient. “Internal validation studies are now underway for the initial MosaiQ applications, with European field trials scheduled to commence early in the third calendar quarter of 2017.  We look forward to sharing the results of the internal validation studies and European field trials when they are completed later this summer.” MosaiQ, Quotient's next-generation automation platform for blood grouping and disease screening, represents a transformative and highly disruptive testing platform for transfusion diagnostics, with an established capability to detect antibodies and antigens.  Feasibility has also been demonstrated with respect to the detection of nucleic acids (DNA or RNA). Through MosaiQ, Quotient aims to deliver substantial value to donor testing laboratories worldwide with a unified instrument platform to be utilized for blood grouping and both serological and molecular disease screening of donated red blood cells and plasma. Assay performance for the initial blood grouping and disease screening applications continues to meet expectations.  The Company has taken the opportunity over the past four weeks to further optimize the spot recognition algorithm for the antibody detection assay. Quotient has commenced formal internal validation studies for the MosaiQ IH Microarray.  These studies are designed to mimic the subsequent field trials.  This work is expected to be completed in July. “The conventional reagent business generated record results in terms of revenue and profitability during fiscal 2017, with total revenues growing 20% year-over-year,” said Paul Cowan. “Quotient generated product sales and gross profit growth of 12% and 11%, respectively, during fiscal 2017.  We are targeting a continuation of solid growth and profitability for this business in the coming fiscal year.” Key revenue and profit results are summarized below (dollar amounts expressed in thousands): Capital expenditures totaled $20.2 million in fiscal 2017 ("FY17"), compared with $29.0 million in fiscal 2016 ("FY16"), reflecting continued investment in the Eysins, Switzerland manufacturing facility and manufacturing equipment for MosaiQ consumables, along with expenditures related to the construction of a new conventional reagent manufacturing facility near Edinburgh, Scotland. Quotient ended FY17 with $20.8 million in cash and other short term investments, $80.7 million of long-term debt and $5.0 million in an offsetting long term cash reserve account.  On April 10, 2017, Quotient completed an equity offering raising $45.2 million, net of expenses. Product sales in the first quarter of fiscal 2018 are expected to be within the range of $5.7 to $6.0 million, compared with $5.7 million for the first quarter of FY17. Quarterly product sales can fluctuate depending upon the shipment cycles for red blood cell based products, which account for approximately two-thirds of current product sales. These products typically experience 13 shipment cycles per year, equating to three shipments of each product per quarter, except for one quarter per year when four shipments occur. The timing of shipment of bulk antisera products to OEM customers may also move revenues from quarter to quarter. Some seasonality in demand is also experienced around holiday periods in both Europe and the United States. As a result of these factors, Quotient expects to continue to see seasonality and quarter-to-quarter variations in product sales. The timing of product development fees included in other revenues is mostly dependent upon the achievement of pre-negotiated project milestones. The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that Quotient will continue as a going concern. However, the Company has incurred net losses from operations in each year since it commenced operations in 2007 and had an accumulated deficit of $193.3 million as of March 31, 2017. Although Quotient's audit is not yet completed, the Company expects that its auditor’s report will reference certain conditions concerning the Company’s overall liquidity position that raise substantial doubt about its ability to continue as a going concern. Quotient will host a conference call on Tuesday, May 23 at 8:00 a.m. Eastern Time to discuss its fourth quarter FY17 and FY17 financial results. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The conference call will be webcast live on the Company’s website at www.quotientbd.com. A replay of this conference call will be available through May 30 by dialing 1-844-512-2921 in the U.S. or 1-412-317-6671 outside the U.S. The replay access code is 13660555. Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The Company’s operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania. This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products, current estimates of first quarter and full year fiscal 2018 operating results and capital expenditures and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceeding; continued or worsening adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements. The Quotient logo and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.


JERSEY, Channel Islands, May 22, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported continued progress on the commercial scale-up of MosaiQ and financial results for its fourth quarter and fiscal year ended March 31, 2017. “Tremendous progress continues to be made towards the full commercial launch of MosaiQ in Europe later this year. The initial manufacturing system for MosaiQ Microarrays is now commissioned and validated. Working with our partner STRATEC, we have now taken delivery of the first “commercially ready” MosaiQ Instrument” said Paul Cowan, Chairman and Chief Executive Officer of Quotient. “Internal validation studies are now underway for the initial MosaiQ applications, with European field trials scheduled to commence early in the third calendar quarter of 2017.  We look forward to sharing the results of the internal validation studies and European field trials when they are completed later this summer.” MosaiQ, Quotient's next-generation automation platform for blood grouping and disease screening, represents a transformative and highly disruptive testing platform for transfusion diagnostics, with an established capability to detect antibodies and antigens.  Feasibility has also been demonstrated with respect to the detection of nucleic acids (DNA or RNA). Through MosaiQ, Quotient aims to deliver substantial value to donor testing laboratories worldwide with a unified instrument platform to be utilized for blood grouping and both serological and molecular disease screening of donated red blood cells and plasma. Assay performance for the initial blood grouping and disease screening applications continues to meet expectations.  The Company has taken the opportunity over the past four weeks to further optimize the spot recognition algorithm for the antibody detection assay. Quotient has commenced formal internal validation studies for the MosaiQ IH Microarray.  These studies are designed to mimic the subsequent field trials.  This work is expected to be completed in July. “The conventional reagent business generated record results in terms of revenue and profitability during fiscal 2017, with total revenues growing 20% year-over-year,” said Paul Cowan. “Quotient generated product sales and gross profit growth of 12% and 11%, respectively, during fiscal 2017.  We are targeting a continuation of solid growth and profitability for this business in the coming fiscal year.” Key revenue and profit results are summarized below (dollar amounts expressed in thousands): Capital expenditures totaled $20.2 million in fiscal 2017 ("FY17"), compared with $29.0 million in fiscal 2016 ("FY16"), reflecting continued investment in the Eysins, Switzerland manufacturing facility and manufacturing equipment for MosaiQ consumables, along with expenditures related to the construction of a new conventional reagent manufacturing facility near Edinburgh, Scotland. Quotient ended FY17 with $20.8 million in cash and other short term investments, $80.7 million of long-term debt and $5.0 million in an offsetting long term cash reserve account.  On April 10, 2017, Quotient completed an equity offering raising $45.2 million, net of expenses. Product sales in the first quarter of fiscal 2018 are expected to be within the range of $5.7 to $6.0 million, compared with $5.7 million for the first quarter of FY17. Quarterly product sales can fluctuate depending upon the shipment cycles for red blood cell based products, which account for approximately two-thirds of current product sales. These products typically experience 13 shipment cycles per year, equating to three shipments of each product per quarter, except for one quarter per year when four shipments occur. The timing of shipment of bulk antisera products to OEM customers may also move revenues from quarter to quarter. Some seasonality in demand is also experienced around holiday periods in both Europe and the United States. As a result of these factors, Quotient expects to continue to see seasonality and quarter-to-quarter variations in product sales. The timing of product development fees included in other revenues is mostly dependent upon the achievement of pre-negotiated project milestones. The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that Quotient will continue as a going concern. However, the Company has incurred net losses from operations in each year since it commenced operations in 2007 and had an accumulated deficit of $193.3 million as of March 31, 2017. Although Quotient's audit is not yet completed, the Company expects that its auditor’s report will reference certain conditions concerning the Company’s overall liquidity position that raise substantial doubt about its ability to continue as a going concern. Quotient will host a conference call on Tuesday, May 23 at 8:00 a.m. Eastern Time to discuss its fourth quarter FY17 and FY17 financial results. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The conference call will be webcast live on the Company’s website at www.quotientbd.com. A replay of this conference call will be available through May 30 by dialing 1-844-512-2921 in the U.S. or 1-412-317-6671 outside the U.S. The replay access code is 13660555. Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The Company’s operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania. This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products, current estimates of first quarter and full year fiscal 2018 operating results and capital expenditures and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceeding; continued or worsening adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements. The Quotient logo and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.


Patent
Microarray Ltd | Date: 2017-02-08

A dressing comprising first and second electrodes, an electrical power supply, and further comprising a physiologically or antimicrobially active precursor substance, the dressing being operable, when placed on a skin site to be treated, for a first treatment period, whereby the electrochemical oxidation or reduction of the precursor substance on one of the electrodes to produce a physiologically active oxidised or reduced substance which is capable of diffusing towards the skin site for the treatment thereof is carried out, and subsequently for a first rest period, the electrochemical oxidation or reduction is stopped, wherein a subsequent treatment periods followed by rest periods are carried out over time.


A skin dressing comprising first and second electrodes, an electrical power supply not electrically connected to either or both of the first and second electrodes, and further comprising a physiologically or antimicrobially active precursor substance, the dressing being operable, when placed on a skin site to be treated, to connect the electrical power supply to both the first and second electrodes, thereby to trigger the electrochemical oxidation or reduction of the precursor substance on one of the electrodes to produce a physiologically or antimicrobially active oxidised or reduced compound which is capable of diffusing towards the skin site for the treatment thereof.


Patent
Microarray Ltd | Date: 2015-03-25

A dressing comprising first and second electrodes, an electrical power supply, and further comprising a physiologically or antimicrobially active precursor substance, the dressing being operable, when placed on a skin site to be treated, for a first treatment period, whereby the electrochemical oxidation or reduction of the precursor substance on one of the electrodes to produce a physiologically active oxidised or reduced substance which is capable of diffusing towards the skin site for the treatment thereof is carried out, and subsequently for a first rest period, the electrochemical oxidation or reduction is stopped, wherein subsequent treatment periods followed by rest periods are carried out over time.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Smart - Proof of Market | Award Amount: 24.95K | Year: 2012

Over the nine months of the project, we firstly intend to contact established companies within the field of water-testing (such as Hach, Palintest, Siemens) to introduce them to our technology and more importantly to ascertain their needs in terms of test requirements. Here we aim to gain an understanding of the tests currently employed by these major companies, with an emphasis being placed towards the more important analytes to be measured (for example total THM measurement, or individual species), the number of tests being taken, and also the accuracy at which the readings need to recorded. Once we have obtained this initial market research, we will then aim to use these preliminary meetings to provide further introductions to possible end-users of the technology. Here we aim to undertake a review of current measurement protocols so we can gain an in depth understanding of present techniques in terms of their limitations and un-met needs. We will then use these findings as a starting point on which to further expand our development protocols. As our final aim is to possibly provide a device which is capable of measurement of a number of different analytes (such as CHCl3, CHBrCl2, CHBr2Cl and CHBr3), we feel it is important to gain an in-depth knowledge of what is required at the user interface. Input from end-users is vital for us to develop a device which is commercially viable. We already have identified THMs as a possible target analyte; however we also seek information regarding specific THM species for us to develop defined measurement protocols. Differing disinfection protocols will lead to the formation of increased levels of particular THM species (such as increased CHBr3 levels when bromination is employed). Once we have taken advice from end users, we can then implement an investigation into time-scales and costings for the development of sensing devices for each of the required analytes. We already have in place a rudimentary ‘proof-of-concept’ development of the methodology required for the determination of one THM species, chloroform. For the determination of chloroform a simple electrochemical technique is employed, upon carbon screen-printed surface that have been modified to microelectrode arrays via our novel fabrication procedures. The measurement protocol is based on the oxidation of the chloroform species on a reverse anodic sweep, where an oxidation peak current is detected and can be related back to the concentration under investigation. To date we have measured down to levels of 1ppm, but we know we need to obtain lower limits of detection in the order of ~80ppm and we require further guidance as to the lower limits of detection required for specific THMs; we intend to obtain this information and further guidance from meetings with potential end users and contacts at each of the highlighted companies. We would also need to investigate our freedom to seek patent protection for our approach process. We would also begin to establish whether specific components of any possible product, could be protected to gain maximum protection. This exercise will also help us identify any competing patents or other obstacles to allow commercialisation. Patents within the infringement period that are not in force, but which may clear a ‘right-to-use’ by virtue of being in the public domain, will also be searched for. When this type of search is followed up with a validity search against any highly relevant patents identified, this is sometimes referred as a clearance search.


Patent
Microarray Ltd | Date: 2012-08-10

This invention relates to improvements to medical devices such as biosensors containing proteins such as oxidoreductases, for example oxidase and/or peroxidase enzymes. More generally it relates to novel compositions containing proteins which are stabilised to ionising radiation.

Loading Microarray Ltd collaborators
Loading Microarray Ltd collaborators